Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.
Takimoto CH, Morrison G, Harold N, Quinn M, Monahan BP, Band RA, Cottrell J, Guemei A, Llorens V, Hehman H, Ismail AS, Flemming D, Gosky DM, Hirota H, Berger SJ, Berger NA, Chen AP, Shapiro JD, Arbuck SG, Wright J, Hamilton JM, Allegra CJ, Grem JL.
Takimoto CH, et al. Among authors: berger sj, berger na.
J Clin Oncol. 2000 Feb;18(3):659-67. doi: 10.1200/JCO.2000.18.3.659.
J Clin Oncol. 2000.
PMID: 10653882
Clinical Trial.